Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Basic fetoprotein (BFP) was measured by enzyme immunoassay in the urine of healthy adults and patients with benign or malignant urological diseases. Urinary BFP level in 34 healthy donors was very low (2.75 +/- 2.27 ng/ml). Since the BFP-positive rate is under 5% in healthy donors and, considering diagnostic efficiency for urological malignancies, a urinary BFP-concentration of 15 ng/ml was used as the cut off value. Urinary BFP was positive in 17.0% of 106 patients with benign urological diseases, in 51.9% of 52 patients with bladder cancer, in 75.0% of 8 patients with renal pelvic or ureteral cancer, in 25.0% of 20 patients with prostate cancer, and in 19.0% of 21 patients with renal cell carcinoma. In 60 patients with urothelial carcinomas, urinary BFP was higher in invasive diseases (greater than pT1) than in superficial diseases (p less than 0.05). The BFP level in urine also increased with a higher histological grade. The positive rate of urinary BFP was 78.9% in patients with invasive diseases and 66.7% in patients with grade 3 diseases. In 44 patients with urothelial carcinomas who underwent urinary cytological examination the positive rate was improved from 38.6% (17/44) to 81.4% (37/44) when measurement of urinary BFP was added. BFP in urine was found to be useful as a tumor marker for urothelial carcinomas. In addition, it was demonstrated that combined examination of urinary cytology with urinary BFP was more efficient for diagnosis of urothelial carcinomas.
 ...
PMID:[The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies]. 169 31

Therapy with proton beam is superior to that with photon beam in concentrating the dose within a lesion. Fifteen patients with urinary malignant tumors were treated by proton irradiation during the period from June, 1985 to March, 1989 at Particle Radiation Medical Center, University of Tsukuba. Four patients were with renal cell carcinoma, five with prostatic cancer and six with bladder cancer. Treatment results were assessed by change in tumor size either three or six months after the irradiation. In all the four cases with renal cell carcinoma, the tumor sizes were found to be unchanged without any enlargement. Of the five cases with prostatic cancer, two showed that the treatment was effective and the tumor sizes in the other three cases were found to be unchanged. In three of the six cases with bladder cancer the tumors disappeared while the treatment was found effective in two other and it did not cause any enlargement of the tumor in the remaining one. Although local control of the tumor was successful in all the cases, one patient with prostatic cancer and three with bladder cancer died of cancer. Various side effects, such as radiation cystitis, were observed. This prospective therapy is expected to replace the conventional photon therapy. However, some improvement is needed to make full use of the advantageous properties in dose distribution. Combination therapy with other general therapy is required for some cases.
 ...
PMID:[Clinical study of proton radiotherapy in urological cancers]. 215 15

Gamma-seminoprotein (gamma-Sm), a potential new marker for prostate cancer, has been evaluated with a sandwich-type enzyme immunoassay (EIA). This assay system has been confirmed to have a sensitivity and detectable range of 3.0 and 3.0-100 ng/ml, respectively, with a high reproducibility (approximately equal to 6% coefficient of variation between assays). A total of 256 serum samples were drawn from normal Japanese subjects for detection of gamma-Sm. Serum gamma-Sm was undetectable (less than 3.0 ng/ml) in 26 samples from 26 females. In 230 male cases, serum gamma-Sm levels ranged from less than 3.0 to 4.0 ng/ml. These values were not related to age. An upper normal limit of 3.6 ng/ml was calculated for 99 percentile Japanese males (n = 103) over 50 years of age. Serum gamma-Sm was detected in 192 untreated male patients with urological diseases. Gamma Sm levels (mean +/- SD) in each disease were as follows: prostate cancer (n = 64) 11.0 +/- 17.9 ng/ml; benign prostatic hypertrophy (n = 50), 3.02 +/- 0.113; bladder cancer (n = 58), 3.13 +/- 0.514; and renal adenocarcinoma (n = 30), 3.26 +/- 1.01. Serum gamma-Sm levels were statistically higher (p less than 0.05) in the prostate cancer group, however, there was no statistical difference in gamma-Sm levels among clinical stages or histopathologic grades. Furthermore, serum gamma-Sm values showed no correlation (r = 0.3870) with prostatic acid phosphatase (PAP), but were slightly correlated to prostate antigen (PA) levels (r = 0.6980) in patients with prostate cancer. These results suggest that gamma-Sm is a potential tumor marker of prostate cancer and that serially detected serum gamma-Sm levels could be used to monitor the disease.
 ...
PMID:Clinical evaluation of gamma-seminoprotein in prostate cancer. 242 39

A new enzymatic method for isolation and determination of urinary polyamines was presented and basically studied in previous report 1 and 2 in comparison with existing techniques. Using the new method, urinary polyamines were isolated and determined in 56 patients with genitourinary cancer. Urinary polyamines were also determined in 63 controls consisting of 20 normal subjects, 25 patients with benign urological disease and 18 patients with BPH. The mean concentrations of Diamine, Spermidine, Spermine in 20 normal subjects were 16.6 +/- 5.8 mumoles/g Cr, 4.7 +/- 2.0 mumoles/g Cr and 0.99 +/- 0.51 mumoles/g Cr respectively. To emphasize the specificity to cancer, the level of positiveness was modified to a higher value than M+3SD. The positive values thus calculated were 40 mumoles/g Cr for Diamine, 15 mumoles/g Cr for Spermidine and 3 mumoles/g Cr for Spermine. The positive ratios of Diamine in patients with early cancer were 43% in renal cell cancer, 20% in pelvic and ureter cancer, 0% in bladder cancer and 20% in prostatic cancer. Those of Spermidine were 29% in renal cell cancer, 0% in pelvic and ureter cancer, 20% in bladder cancer and 40% in prostatic cancer. Those of Spermine were 29% in renal cell cancer, 20% in pelvic and ureter cancer, 20% in bladder cancer and 0% in prostatic cancer. In early diagnoses, Diamine indicated high positive ratios to renal cell cancer and Spermidine to prostatic cancer. Relatively high positive ratios were demonstrated, when any one of the isolated polyamines was found positive: namely, 57% in renal cell cancer, 20% in pelvic and ureter cancer, 30% in bladder cancer and 40% in prostatic cancer.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Detection of urinary polyamine by a new enzymatic differential assay. (III). Studies on urinary polyamines in patients with malignant genitourinary diseases]. 242 8

Clinical and laboratory studies have confirmed the efficacy of alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCH) as tumor markers in the diagnosis, monitoring and assessment of prognosis in cases of testicular tumor. Serum AFP level is positive in 75% of yolk sac tumors, 70% of embryonal carcinomas and 62% of teratomas. All cases of choriocarcinoma show elevated serum hCG. In the treatment of prostatic cancer, prostatic acid phosphatase (PAP), prostatic-specific antigen (PA) and gamma-seminoprotein (gamma-Sm) are important serum markers, and the RIA method has improved their specificity and sensitivity. These markers are also correlated well with therapeutic efficacy. Especially, improvement of the serum PAP level in patients with stage C and D cancer indicates prolongation of survival time. Over 90% of the metastatic lesions of prostatic cancer are encountered in the skeletal system. Thus, serum alkaline phosphatase and urinary hydroxyproline are considered to be useful markers for indicating bone involvement. In other urological malignancies, there are no specific tumor markers. As non-specific markers for renal cell carcinoma, ESR, LDH, CEA, alpha 2-globulin, haptoglobin, fibrinogen and various hormones have been investigated. In the treatment of bladder cancer, it is important to distinguish the malignant potential of the tumor. From this viewpoint, various immunohistochemical investigations and flow cytometric analysis are now in progress. It is expected that some of the findings of the studies could prove to be of clinical use in the near future.
 ...
PMID:[Significance of tumor markers in the treatment of urological malignancies]. 244 94

Recently, various progresses have been made in the treatment of the genitourinary malignant tumors. Effectiveness of the intravesical instillation of anti-cancer agents and biological reaction modifiers has been proved in the treatment and prevention of the superficial bladder cancer. Among them, superiority of BCG is now attracting attention of all the urologists. For the invasive bladder cancer, the M-VAC therapy (the combination chemotherapy of methotrexate, vinblastine, actinomycin and cis-platinum) has been found to be extremely useful. The multidisciplinary approach for the down-staging of the advanced bladder cancer has been advocated around the world. As for the prostatic cancer, that of the high stage is the main concern of the Japanese urologists, since the mass screening of the prostatic cancer has not prevailed in Japan. The LHRH agonists or the blockers of the androgen receptor have been replacing the classic antiandrogenic treatment consisting of castration and estrogen administration to treat the advanced carcinoma. On the other hand, the nerve-sparing total prostatectomy has been recommended for the low stage cancer by Walsh and associates to preserve potency. The testicular cancer has been most effectively treated with the combined chemotherapy. The PVB and VAB therapy are well known in the world. Lately, VP-16 (etoposide) was found to be a useful salvage agent. The least advance has been made in the treatment of renal cell carcinoma, although interferon therapy or LAK cell adoptive immunotherapy appears attractive.
 ...
PMID:[Treatment of genitourinary malignancy--present concept and controversy]. 244 33

The use of megestrol acetate in treatment of malignancy (endometrial carcinoma, ovarian cancer, prostate cancer, breast cancer, renal cell carcinoma, malignant melanoma), endometrial hyperplasia, benign prostatic hypertrophy, contraception, anorexia, cachexia and weight loss is reviewed, concluding with a toxicity profile. Megestrol acetate was introduced in 1971 for treatment of endometrial carcinoma. Megestrol acetate is probably effective in proportion to the number of cytoplasmic progesterone receptors, but it has not been tested in a Phase III trial. For ovarian cancer it has been reported to be effective in 1 trail at doses of 800 mg/day. Prostate cancer, although difficult to assess, responds to megestrol acetate at doses of 120 mg/day because of its suppression of gonadotropins, its inhibition of 5alpha-reductase and its binding to the dihydrotestosterone receptor. Megestrol acetate permits a lower dose of diethylstilbestrol, and thus lower toxicity. There is apparently a dose-response between megestrol acetate and breast cancer, along with a response dependent on the number and type of estrogen and progestin receptors. Responses are better in postmenopausal women, and additive with other agents such as tamoxifen and mitomycin C. The medium duration of effect is 6-8 months. It has no effect on renal cancer or malignant melanoma. Megestrol acetate can be considered as an effective medical alternative to surgery for endometrial hyperplasia or benign prostatic hypertrophy. As a contraceptive in inhibits sperm transport rather than ovulation, but also causes irregular bleeding. Megestrol acetate has few side effects, and has the advantage of stimulating appetite and weight gain, a benefit in cancer patients.
 ...
PMID:Megestrol acetate: clinical experience. 247 90

Immunocytochemical screening of bladder tumors with an antibody to beta-human chorionic gonadotrophin (hCG) demonstrates a correlation with malignant behavior in that 0 of 20 G1M0, 5 of 20 G3M0, and 11 of 20 G2/3M + showed strong staining, while only 2/20 G3 Ca prostate and 0/18 renal cell carcinoma showed weak staining. There was a suggestion that hCG positive bladder cancer responded less well to chemotherapy (1 of 12 hCG positive and 6 of 13 hCG negative patients achieved a complete or partial response) and also patients whose tumors showed strong hCG staining did less well after radiotherapy, though paradoxically patients showing only occasional stained cells did better than patients whose tumor showed no staining. The possible significance of these observations in relation to recent observations on the mechanisms of trophoblast escape from immune surveillance is discussed.
 ...
PMID:Clinicopathological significance of immunoreactive beta-hCG production by bladder cancer. 247 41

Regional lymph node dissection in the management of genitourinary (GU) neoplasms is controversial but is based on a 17 year clinical experience and the achievement of survival figures as good or better than those achieved by any other modality of therapy. Lymphadenectomy has proved to be effective in curing patients with metastatic testicular cancer, renal cell carcinoma and transitional cell carcinoma. Its efficacy in prostate cancer is much less certain and remains largely a staging procedure.
 ...
PMID:The value of regional lymph node dissection in genitourinary cancer. 277 63

Tumor-to-tumor metastases are uncommon despite the fact that the presence of two or more malignancies in a single patient is not a rare occurrence. The most frequent donor tumors are the lung, prostate, and thyroid gland, whereas renal cell carcinoma is by far the most common recipient. In this report we describe a patient dying of metastatic malignant melanoma and locally advanced prostate cancer in which the melanoma metastasized to the prostatic adenocarcinoma. The prostatic primary was well differentiated and stained positively with prostate-specific antigen and prostatic acid phosphatase, whereas the melanoma contained abundant melanin pigment and stained positively for S-100 protein. This is the second reported instance of prostatic carcinoma as the recipient in a case of tumor-to-tumor metastases and the first in the English language literature.
 ...
PMID:Malignant melanoma with metastasis to adenocarcinoma of the prostate. 291 Apr 17


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>